http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-598082-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b58f981963f6d55d627139e778c4ef7b
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-232
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-232
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24
filingDate 2010-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3efaccc1d8e1a3aecd1cc5e59200d8db
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fdf85dc3a83c2ce1a49f70a058982d24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63fa334611980b35a0f48d45ddb5f82a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_651d433c3d5d329cad411386b026f1dd
publicationDate 2013-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber NZ-598082-A
titleOfInvention Pharmaceutical composition including a dha ester to be parenterally administered
abstract 598082 Disclosed herein is a pharmaceutical composition to be parenterally administered, including submicronic ester particles of docosahexaenoic acid, dispersed in an aqueous phase using a mixture of at least two surfactants selected from among a) at least one polyoxyethylene fatty acid ester and b) at least one phospholipid derivative selected from the group of consisting of lecithins of natural origin, phospholipids of natural origin, synthetic phospholipids and mixtures thereof. The present invention also relates to the method for preparing said pharmaceutical composition.
priorityDate 2009-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411029818
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID445580

Total number of triples: 32.